A growing number of clinicians rely on AdaptDx to detect age-related macular degeneration in their adult patients. Our customers tell the story of how they’re fighting against blindness caused by AMD.
The research behind the AdaptDx is solid. Its specificity and sensitivity are better than a visual field for glaucoma. And macular degeneration is 3 times more prevalent then glaucoma and diabetic retinopathy combined. So why would I not use the AdaptDx test on everybody over the age of 50? Oh, and did I mention it catches subclinical AMD before you can see drusen or mottling in the eye itself?
The MacuLogix AdaptDx performs a robust and reliable test of central retinal dysfunction and establishes a proven early biomarker for age-related macular degeneration. The elegance of the instrument lies in its simplicity: an easy procedure for the patient, a short test duration, and an unambiguous data output for the clinician.
The customer service education training and support that I receive from MacuLogix is second to none of any of the other companies in our profession.
The AdaptDx has been a wonderful addition to our practice. Not only does it allow us to help detect macular degeneration at its earliest subclinical state but also then allows us to help educate patients with lifestyle changes helping to prolong the disease process and improve quality of living. It has been a wonderful practice builder by setting us apart as a very high-quality eye care facility providing better patient confidence in the care that they are being provided.
Prior to having the AdaptDx, I struggled with patients having complaints of night vision issues. Providing a recheck of their refractive findings and another look at their retina always came up negative. I knew this patient was providing me a legitimate complaint, but I could provide no clinical basis for this complaint. Now we test these patients using the AdaptDx and in minutes discover if their complaint is due to subclinical AMD. This allows me to not only diagnose their complaint, but the patient is also able to start treatment even earlier with supplementation and making lifestyle changes.
The AdaptDx is the kind of optometric instrument that once implemented in your practice makes you think how you did so without it all this time. The ability to find AMD years before seeing changes in the retina by photography or OCT makes it a medical necessity for my practice and patients. Once I learned about it, I could no longer neglect that segment of my practice and had to have it! It is easy to use, profitable, and the right thing to do for my patients. And our patients deserve the best!
The MacuLogix AdaptDx dark adaptometer is the first device of its kind that will provide me with a quantifiable result that can be monitored over time. It allows me to track the function of a patient’s macular rod photoreceptors, which is a very specific biomarker for AMD. In my opinion, this device is a game-changer in any practice committed to preserving sight. Having the ability to diagnose AMD in patients with symptoms but little to no clinical signs has taken my confidence to the next level.
Outside of the lane, there are four essential diagnostic tests that I couldn’t practice without: OCT, fundus camera, visual field, and the AdaptDx.
Having had the AdaptDx in my practice for almost 5 years has reinforced my confidence level in diagnosing AMD early with 90% sensitivity and specificity. My patients appreciate this technology and early diagnosis so that we can better monitor their progress and guide them with preventive measures. My patients recognize our practice as an AMD Center of Excellence with a commitment to preventing blindness through early diagnosis and management. MacuLogix has given our doctors the tool to be leaders in early AMD diagnosis.
Having been a Vision Source Administrator for nearly 15 years, I know the mindset of the prototypical Vision Source doctor, and it is this: seek out and deliver the highest outcome patient care using the most up-to-date technology that is based on the latest peer-reviewed research. While accomplishing this worthy goal, the Vision Source doctor also watches to be certain that this increased level of care will simultaneously enhance the practice’s business well-being and also save money for the overall health care system with early diagnosis and treatment. Having also been trained extensively on dark adaptometry technology, I can wholeheartedly say that the AdaptDx instrument checks every single box for the Vision Source practitioner to accomplish all of these patient goals in the early detection and treatment of subclinical AMD.